Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study.
<h4>Background/aims</h4>Non-alcoholic fatty liver disease (NAFLD) represents a significant public health issue. Identifying patients with simple steatosis from those with non-alcoholic steatohepatitis (NASH) is crucial since NASH is correlated with increased morbidity and mortality. Seru...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/329e810f046c49ec9cdd03bbadbcecc5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:329e810f046c49ec9cdd03bbadbcecc5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:329e810f046c49ec9cdd03bbadbcecc52021-12-02T20:16:12ZAssessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study.1932-620310.1371/journal.pone.0260313https://doaj.org/article/329e810f046c49ec9cdd03bbadbcecc52021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0260313https://doaj.org/toc/1932-6203<h4>Background/aims</h4>Non-alcoholic fatty liver disease (NAFLD) represents a significant public health issue. Identifying patients with simple steatosis from those with non-alcoholic steatohepatitis (NASH) is crucial since NASH is correlated with increased morbidity and mortality. Serum-based markers, including adipokines and cytokines, are important in the pathogenesis and progression of NAFLD. Here we assessed the usefulness of such markers in patients with NAFLD.<h4>Methods</h4>This prospective, cross-sectional study included 105 adult patients with varying severity of NAFLD. Twelve serum-based markers were measured by 3 biochip platforms and 2 enzyme-linked immunosorbent assay (ELISA) methods. We also developed a NAFLD individual fibrosis index (NIFI) using the serum-based markers mostly correlated with fibrosis severity.<h4>Results</h4>Sixty-one out of 105 patients were male (58.1%) with mean age was 53.5 years. Higher Interleukin-6 (IL-6) increased (p = 0.0321) and lower Matrix Metalloproteinase-9 (MMP-9) serum levels (p = 0.0031) were associated with higher fibrosis as measured by Fibroscan® in multivariable regression analysis. Using receiver-operating characteristic (ROC) curve analysis for the NIFI, area under the curve for predicting Fibroscan values ≥ 7.2 kPa was 0.77 (95%CI: 0.67, 0.88, p<0.001), with sensitivity of 89.3%, specificity of 57.9% and a positive likelihood ratio of 2.8.<h4>Conclusions</h4>Increasing fibrosis severity in NAFLD is associated with differential expression of IL-6 and MMP-9. NIFI could be valuable for the prediction of advanced NAFLD fibrosis and potentially help avoid unnecessary interventions such as liver biopsy in low-risk patients.Atul GoyaleAnjly JainColette SmithMargarita PapatheodoridiMarta Guerrero MisasDavide RoccarinaLaura Iogna PratDimitri P MikhailidisDevaki NairEmmanuel TsochatzisPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11, p e0260313 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Atul Goyale Anjly Jain Colette Smith Margarita Papatheodoridi Marta Guerrero Misas Davide Roccarina Laura Iogna Prat Dimitri P Mikhailidis Devaki Nair Emmanuel Tsochatzis Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. |
| description |
<h4>Background/aims</h4>Non-alcoholic fatty liver disease (NAFLD) represents a significant public health issue. Identifying patients with simple steatosis from those with non-alcoholic steatohepatitis (NASH) is crucial since NASH is correlated with increased morbidity and mortality. Serum-based markers, including adipokines and cytokines, are important in the pathogenesis and progression of NAFLD. Here we assessed the usefulness of such markers in patients with NAFLD.<h4>Methods</h4>This prospective, cross-sectional study included 105 adult patients with varying severity of NAFLD. Twelve serum-based markers were measured by 3 biochip platforms and 2 enzyme-linked immunosorbent assay (ELISA) methods. We also developed a NAFLD individual fibrosis index (NIFI) using the serum-based markers mostly correlated with fibrosis severity.<h4>Results</h4>Sixty-one out of 105 patients were male (58.1%) with mean age was 53.5 years. Higher Interleukin-6 (IL-6) increased (p = 0.0321) and lower Matrix Metalloproteinase-9 (MMP-9) serum levels (p = 0.0031) were associated with higher fibrosis as measured by Fibroscan® in multivariable regression analysis. Using receiver-operating characteristic (ROC) curve analysis for the NIFI, area under the curve for predicting Fibroscan values ≥ 7.2 kPa was 0.77 (95%CI: 0.67, 0.88, p<0.001), with sensitivity of 89.3%, specificity of 57.9% and a positive likelihood ratio of 2.8.<h4>Conclusions</h4>Increasing fibrosis severity in NAFLD is associated with differential expression of IL-6 and MMP-9. NIFI could be valuable for the prediction of advanced NAFLD fibrosis and potentially help avoid unnecessary interventions such as liver biopsy in low-risk patients. |
| format |
article |
| author |
Atul Goyale Anjly Jain Colette Smith Margarita Papatheodoridi Marta Guerrero Misas Davide Roccarina Laura Iogna Prat Dimitri P Mikhailidis Devaki Nair Emmanuel Tsochatzis |
| author_facet |
Atul Goyale Anjly Jain Colette Smith Margarita Papatheodoridi Marta Guerrero Misas Davide Roccarina Laura Iogna Prat Dimitri P Mikhailidis Devaki Nair Emmanuel Tsochatzis |
| author_sort |
Atul Goyale |
| title |
Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. |
| title_short |
Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. |
| title_full |
Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. |
| title_fullStr |
Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. |
| title_full_unstemmed |
Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. |
| title_sort |
assessment of non-alcoholic fatty liver disease (nafld) severity with novel serum-based markers: a pilot study. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2021 |
| url |
https://doaj.org/article/329e810f046c49ec9cdd03bbadbcecc5 |
| work_keys_str_mv |
AT atulgoyale assessmentofnonalcoholicfattyliverdiseasenafldseveritywithnovelserumbasedmarkersapilotstudy AT anjlyjain assessmentofnonalcoholicfattyliverdiseasenafldseveritywithnovelserumbasedmarkersapilotstudy AT colettesmith assessmentofnonalcoholicfattyliverdiseasenafldseveritywithnovelserumbasedmarkersapilotstudy AT margaritapapatheodoridi assessmentofnonalcoholicfattyliverdiseasenafldseveritywithnovelserumbasedmarkersapilotstudy AT martaguerreromisas assessmentofnonalcoholicfattyliverdiseasenafldseveritywithnovelserumbasedmarkersapilotstudy AT davideroccarina assessmentofnonalcoholicfattyliverdiseasenafldseveritywithnovelserumbasedmarkersapilotstudy AT lauraiognaprat assessmentofnonalcoholicfattyliverdiseasenafldseveritywithnovelserumbasedmarkersapilotstudy AT dimitripmikhailidis assessmentofnonalcoholicfattyliverdiseasenafldseveritywithnovelserumbasedmarkersapilotstudy AT devakinair assessmentofnonalcoholicfattyliverdiseasenafldseveritywithnovelserumbasedmarkersapilotstudy AT emmanueltsochatzis assessmentofnonalcoholicfattyliverdiseasenafldseveritywithnovelserumbasedmarkersapilotstudy |
| _version_ |
1718374517339848704 |